SELLAS wants to sell us an Immunotherapy for Mesothelioma

After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences.

---

City: Zug (Zurich-area), Switzerland

Founded: 2012

Employees: 11 – 50

Financial Data: None available…what a secretive cohort.

Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on immunotherapies to treat multiple myeloma and ovarian cancer. It has branched out to mesothelioma, a cancer with a poor prognosis linked to the inhalation of asbestos.

Comment: The company just received Fast Track Designation for its lead candidate, Galinpepimut-S, which it licensed from Memorial Sloan Kettering Cancer Center. The treatment is currently performing admirably in Phase II clinical trials for Malignant Pleural Mesothelioma, inducing CD8 and CD4+ T cells with a favorable tolerability and safety profile.

Feature Image Credit: Labiotech Map

Organoids in cancer research: Paving the way for faster drug development across cancer indications

This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever.

Register now